DK1143977T3 - 2-oxy-benzoxazinonderivater til behandling af obesitas - Google Patents

2-oxy-benzoxazinonderivater til behandling af obesitas

Info

Publication number
DK1143977T3
DK1143977T3 DK00900082T DK00900082T DK1143977T3 DK 1143977 T3 DK1143977 T3 DK 1143977T3 DK 00900082 T DK00900082 T DK 00900082T DK 00900082 T DK00900082 T DK 00900082T DK 1143977 T3 DK1143977 T3 DK 1143977T3
Authority
DK
Denmark
Prior art keywords
obesity
oxy
treatment
benzoxazinone derivatives
benzoxazinone
Prior art date
Application number
DK00900082T
Other languages
Danish (da)
English (en)
Inventor
Harold Francis Hodson
Christopher Robert Dunk
Richard M J Palmer
Robert Downham
Timothy John Mitchell
Beverley Jane Carr
Original Assignee
Alizyme Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9900413.7A external-priority patent/GB9900413D0/en
Priority claimed from GBGB9917294.2A external-priority patent/GB9917294D0/en
Application filed by Alizyme Therapeutics Ltd filed Critical Alizyme Therapeutics Ltd
Application granted granted Critical
Publication of DK1143977T3 publication Critical patent/DK1143977T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DK00900082T 1999-01-08 2000-01-06 2-oxy-benzoxazinonderivater til behandling af obesitas DK1143977T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9900413.7A GB9900413D0 (en) 1999-01-08 1999-01-08 Inhibitors
GBGB9917294.2A GB9917294D0 (en) 1999-07-22 1999-07-22 Inhibitors
PCT/GB2000/000032 WO2000040247A1 (en) 1999-01-08 2000-01-06 2-oxy-benzoxazinone derivatives for the treatment of obesity

Publications (1)

Publication Number Publication Date
DK1143977T3 true DK1143977T3 (da) 2005-08-15

Family

ID=26314965

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00900082T DK1143977T3 (da) 1999-01-08 2000-01-06 2-oxy-benzoxazinonderivater til behandling af obesitas

Country Status (24)

Country Link
US (4) US6624161B2 (zh)
EP (1) EP1143977B3 (zh)
JP (1) JP3822439B2 (zh)
KR (1) KR100678998B1 (zh)
CN (2) CN1915981B (zh)
AR (1) AR022204A1 (zh)
AT (1) ATE293447T1 (zh)
AU (1) AU765147C (zh)
CA (1) CA2359819C (zh)
CH (1) CH1143977H1 (zh)
DE (1) DE60019555C5 (zh)
DK (1) DK1143977T3 (zh)
ES (1) ES2240052T7 (zh)
HK (2) HK1047588B (zh)
HU (1) HUP0105003A3 (zh)
MX (1) MXPA01006921A (zh)
MY (1) MY122578A (zh)
NO (1) NO333922B1 (zh)
NZ (1) NZ512740A (zh)
PL (1) PL207383B1 (zh)
PT (1) PT1143977E (zh)
RU (1) RU2245331C2 (zh)
SI (1) SI1143977T1 (zh)
WO (1) WO2000040247A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022204A1 (es) * 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
GB0001572D0 (en) * 2000-01-24 2000-03-15 Alizyme Therapeutics Ltd Inhibitors
US6504028B2 (en) * 2000-07-11 2003-01-07 The Procter & Gamble Co. Process for preparing benzoxazin-4-one polymer conjugates
JP2005504043A (ja) 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． 生物学的に活性な金属ペプチド類のペプチド模倣体類
PL368994A1 (en) * 2001-08-30 2005-04-04 Alizyme Therapeutics Limited Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
EP1467978A4 (en) * 2001-12-20 2005-11-02 Osi Pharm Inc "COMPOUNDS THAT CONTAIN VACCINATES DRUG LIPASE, THEIR SYNTHESIS AND USE"
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
CA2530634A1 (en) * 2003-06-12 2004-12-23 Menachem Rubinstein Methods of treating obesity and related disorders using tellurium and selenium compounds
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
US20090082435A1 (en) * 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
US20090208584A1 (en) * 2005-06-09 2009-08-20 Tomohiro Yoshinari Solid preparation
JP2010254623A (ja) * 2009-04-24 2010-11-11 Takeda Chem Ind Ltd ベンゾオキサジノン化合物の結晶
US9237762B2 (en) 2010-05-24 2016-01-19 Swedish Oat Fiber Ab Aqueous dispersion comprising galactolipids and method for production thereof
WO2013092786A1 (en) 2011-12-23 2013-06-27 Norgine B.V. Compositions comprising cetilistat
NL2009995C2 (en) * 2011-12-23 2013-09-18 Norgine Bv Compositions.
DE202012104963U1 (de) 2012-12-19 2013-01-14 Norgine B.V. Cetilistat aufweisende Zusammensetzungen
CN103936687B (zh) * 2014-03-24 2016-03-30 重庆东得医药科技有限公司 一种制备西替利司他的方法
CN104374836A (zh) * 2014-09-19 2015-02-25 安徽安科生物工程（集团）股份有限公司 西替利司他及有关杂质的hplc测定方法
CN105622538B (zh) * 2014-10-27 2019-02-01 中国医学科学院药物研究所 一锅法高收率制备新利司他
CN104341370B (zh) * 2014-11-11 2017-02-22 山东创新药物研发有限公司 一种西替利司他的制备方法
CN105669585A (zh) * 2016-01-06 2016-06-15 北京修正创新药物研究院有限公司 一种新利司他的制备方法
CN105566164A (zh) * 2016-01-06 2016-05-11 北京修正创新药物研究院有限公司 一种新利司他杂质的制备方法
WO2018011676A1 (en) * 2016-07-11 2018-01-18 Symed Labs Limited Novel processes for the preparation of 2-oxy-benzoxazinone derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE246996C (zh)
US4657893A (en) * 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4665070A (en) * 1985-06-25 1987-05-12 Syntex (U.S.A.) Inc. 2-oxy-4H-3,1-benzoxazin-4-ones and pharmaceutical use
US4745116A (en) * 1985-06-25 1988-05-17 Syntex (U.S.A.) Inc. 2-oxy-4H-3,1-benzoxazin-4-ones and related compounds and pharmaceutical use
DD246996A1 (de) * 1986-02-26 1987-06-24 Univ Leipzig Verfahren zur herstellung von gegebenenfalls substituierten 2-alkoxy- bzw. 2-aroxy-3,1-benzoxazin-4-onen
CA1309556C (en) * 1987-06-09 1992-10-27 Masayuki Kokubo 4h-3,1-benzoxazin-4-one compounds and pharmaceutical composition thereoffor the inhibition of serine proteases
US5652237A (en) 1994-09-09 1997-07-29 Warner-Lambert Company 2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes
US5985872A (en) * 1995-05-24 1999-11-16 G.D. Searle & Co. 2-amino-benzoxazinones for the treatment of viral infections
US5776756A (en) * 1995-08-31 1998-07-07 Toyo Hakko Co., Ltd. Fermentation compositions having superoxide dismutating activity and an antihypertensive agent for treatment of constipation each having the superoxide dismutating activity
US6139833A (en) * 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
US6136566A (en) * 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6207371B1 (en) * 1996-10-04 2001-03-27 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
CN1280574A (zh) * 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
US6080576A (en) * 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
AR022204A1 (es) 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.

Also Published As

Publication number Publication date
HK1103928A1 (en) 2007-12-28
AU1884600A (en) 2000-07-24
CA2359819C (en) 2008-08-12
CN1359378A (zh) 2002-07-17
US20030195206A1 (en) 2003-10-16
DE60019555T2 (de) 2006-02-23
PT1143977E (pt) 2005-08-31
MY122578A (en) 2006-04-29
AR022204A1 (es) 2002-09-04
HK1047588A1 (en) 2003-04-24
CN1315813C (zh) 2007-05-16
HUP0105003A3 (en) 2004-11-29
WO2000040247A9 (en) 2002-10-24
RU2245331C2 (ru) 2005-01-27
KR100678998B1 (ko) 2007-02-07
AU765147B2 (en) 2003-09-11
JP3822439B2 (ja) 2006-09-20
CN1915981A (zh) 2007-02-21
WO2000040247A8 (en) 2001-02-15
ATE293447T1 (de) 2005-05-15
EP1143977B3 (en) 2012-10-24
DE60019555D1 (de) 2005-05-25
US20110065697A1 (en) 2011-03-17
CA2359819A1 (en) 2000-07-13
JP2002534388A (ja) 2002-10-15
ES2240052T3 (es) 2005-10-16
US8877750B2 (en) 2014-11-04
EP1143977B1 (en) 2005-04-20
NO20013381D0 (no) 2001-07-06
US7858617B2 (en) 2010-12-28
WO2000040247A1 (en) 2000-07-13
MXPA01006921A (es) 2003-06-04
NO20013381L (no) 2001-09-07
KR20020000542A (ko) 2002-01-05
US6624161B2 (en) 2003-09-23
NZ512740A (en) 2003-10-31
HUP0105003A2 (en) 2002-06-29
DE60019555C5 (de) 2009-07-09
US20080161301A1 (en) 2008-07-03
SI1143977T1 (zh) 2005-08-31
PL207383B1 (pl) 2010-12-31
EP1143977A1 (en) 2001-10-17
US20030027821A1 (en) 2003-02-06
CN1915981B (zh) 2011-09-28
ES2240052T7 (es) 2013-02-14
NO333922B1 (no) 2013-10-21
CH1143977H1 (fr) 2007-02-15
AU765147C (en) 2007-05-31
HK1047588B (zh) 2007-08-24
US7825113B2 (en) 2010-11-02

Similar Documents

Publication Publication Date Title
DK1143977T3 (da) 2-oxy-benzoxazinonderivater til behandling af obesitas
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1427437T3 (da) Oxyntomodulin til forebyggelse eller behandling af overvægt
DK1173431T3 (da) Fremgangsmåde til fremstilling af citalopram
IS6286A (is) Efnasambönd til meðhöndlunar á blóðþurrð
DK1105382T3 (da) Fremgangsmåde til fremstilling af citalopram
IS6103A (is) Adamantan afleiður
DK1159274T3 (da) Fremgangsmåde til fremstilling af citalopram
DE60021217D1 (de) Ostomievorrichtung
DK1077940T3 (da) 4-Phenylpiperidiner til behandling af pruritiske dermatoser
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
IS5982A (is) Aðferð til framleiðslu á 5-sýanóþalíði
DK1165576T3 (da) Fremgangsmåde til fremstilling af amin-platin-komplekser
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
DK1206436T3 (da) Retinoider til behandling af emfysem
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1110922T3 (da) Fremgangsmåde til termisk behandling af melformede råmaterialer
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
FR2791258B1 (fr) Composition amincissante
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1228056T3 (da) Fremgangsmåde til fremstilling af citalopram
DE50009340D1 (de) Einstelleinrichtung
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme